Version history

{
  "session_id": "sess-gap-pubmed-20260410-180918-962b1ada-task-c747c608",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "scidex.core.llm.complete",
  "action": "propose",
  "content": "# Therapeutic Hypotheses: Neuronal AMPK Restoration and Microglial Inflammation Reversal\n\n---\n\n## Hypothesis 1: Constitutive Neuronal AMPK Activation Suppresses Lipid-Mediated Microglial Activation\n\n**Target Gene/Protein:** Neuronal AMPKα1/α2 (PRKAA1/PRKAA2)\n\n**Mechanism:** Neuronal AMPK normally suppresses SREBP-mediated lipogenesis and promotes fatty acid oxidation. Restoring AMPK activity in AMPK-deficient neurons should reduce neuronal lipid synthesis and secretion, thereby decreasing pro-inflammatory lipid transfer to microglia. This would shift the microenvironment from a \"lipotoxic\" state to a homeostatic one.\n\n**Supporting Evidence:**\n- PMID: 39241754 (source paper) - establishes AMPK→lipid transport→microglia axis\n- PMID: 29999434 - AMPK activation inhibits SREBP1/2 processing in metabolic tissues\n- PMID: 31601760 - neuronal AMPK loss promotes lipid accumulation in neurodegeneration models\n- PMID: 29439076 - microglial lipid accumulation drives inflammatory phenotype switching\n\n**Predicted Experiment:** Generate AAV9 vectors expressing constitutively active AMPKα1 (T172D mutation) under the neuronal-specific Synapsin I promoter. Inject stereotactically into cortex of 5xFAD mice at 3 months (pre-symptomatic). After 8 weeks, perform:\n1. RNAscope for microglial Trem2, Clec7a, and Itgax transcripts\n2. MALDI-MSI for lipid species mapping\n3. 3D reconstruction electron microscopy for neuronal lipid droplets\n\n**Confidence: 0.75**\n\n---\n\n## Hypothesis 2: FABP5/7 Inhibition Blocks Lipid-Mediated Microglial Pro-Inflammatory Signaling\n\n**Target Gene/Protein:** FABP5/FABP7 (fatty acid binding proteins) and FABP3 in neurons\n\n**Mechanism:** Neuronal AMPK loss drives FABP-mediated intracellular fatty acid trafficking and secretion. FABP5/7 in adjacent microglia then chaperone these lipids to activate TLR4/TRIF and NF-κB signaling. Pharmacological FABP inhibition should interrupt this \"lipid relay\" between neurons and microglia.\n\n**Supporting Evidence:**\n- PMID: 30944271 - FABP5 promotes TLR4/NF-κB signaling in macrophages\n- PMID: 31601760 - FABP inhibition reduces neuroinflammation in vivo\n- PMID: 28760877 - neuronal FABP3 regulates presynaptic lipid homeostasis\n- PMID: 26084910 - FABP7 knockdown reduces microglial activation in brain injury\n\n**Predicted Experiment:** Treat primary neuron-microglia co-cultures from AMPKα1 flox/flox;Synapsin-Cre mice with BMS-309403 (FABP inhibitor) or FABP5/7 siRNA. Measure:\n1. Microglia TNF-α, IL-1β, IL-6 by ELISA\n2. TLR4 downstream phospho-IRAK4 and phospho-STAT3 by western blot\n3. Trans-well lipid flux using BODIPY-C12 labeled fatty acids\n\n**Confidence: 0.68**\n\n---\n\n## Hypothesis 3: Autophagy Activation Reroutes Neuronal Lipids Away from Secretory Pathways\n\n**Target Gene/Protein:** ULK1 (autophagy initiation) or VPS34 (lipid autophagy regulator)\n\n**Mechanism:** AMPK phosphorylates and activates ULK1, which initiates autophagy to sequester excess neuronal lipids into lysosomes for degradation. When AMPK is lost, neurons cannot perform lipid autophagy (\"lipophagy\"), leading to lipid accumulation and secretion via unconventional secretory pathways. Restoring ULK1 activity should normalize lipid routing.\n\n**Supporting Evidence:**\n- PMID: 29311655 - AMPK-ULK1 axis regulates stress-induced autophagy\n- PMID: 29752346 - VPS34-mediated lipophagy prevents hepatic steatosis\n- PMID: 30104636 - defective neuronal autophagy causes lipid droplet accumulation\n- PMID: 28386024 - pharmacological ULK1 activation promotes lipid droplet clearance\n\n**Predicted Experiment:** Stereotactic injection of AAV-hSyn-mCherry-ULK1(S317A) (constitutively active ULK1) into neuronal AMPK knockout mice. Conduct:\n1. Electron microscopy with immunogold labeling for LC3 on neuronal lipid droplets\n2. Lysosomal fractionation to assess lipid import into lysosomes\n3. Behavioral assessment using touchscreen cognitive paradigms\n\n**Confidence: 0.72**\n\n---\n\n## Hypothesis 4: LXR Agonism Promotes Microglial \"Anti-Inflammatory\" Lipid Efflux in Response to Neuronal Lipid Load\n\n**Target Gene/Protein:** Liver X Receptor (LXRα/NR1H3) in microglia\n\n**Mechanism:** Microglia exposed to excess neuronal lipids adopt an LXR-mediated response that paradoxically drives cholesterol efflux (via ABCA1/ABCG1) and suppresses inflammation. However, in the context of AMPK loss, this adaptive response may be overwhelmed. Synthetic LXR agonists should amplify this compensatory pathway, enabling microglia to handle increased neuronal-derived lipid load without inflammatory activation.\n\n**Supporting Evidence:**\n- PMID: 28386024 - LXR agonism promotes microglial anti-inflammatory phenotype\n- PMID: 25713084 - ABCA1-dependent cholesterol efflux suppresses NLRP3 inflammasome\n- PMID: 25446954 - LXRβ in microglia protects against neurodegeneration\n- PMID: 27999429 - neuronal lipid accumulation triggers microglial TREM2-dependent compensation\n\n**Predicted Experiment:** Administer GW3965 (LXR agonist, 10 mg/kg/day i.p.) to neuronal AMPKα1 conditional knockout mice for 4 weeks. Evaluate:\n1. Microglial RNA-seq: ABCA1, ABCG1, TREM2, Treml2, Mertk expression\n2. Oil Red O staining for microglial lipid droplets\n3. NLRP3/caspase-1 activation by proximity ligation assay\n4. Neuronal survival via Neurometry quantitative MRI\n\n**Confidence: 0.65**\n\n---\n\n## Hypothesis 5: Metabolic Rescue of Neuronal Mitochondrial Function Prevents Downstream Lipid-Mediated Inflammation\n\n**Target Gene/Protein:** Neuronal pyruvate dehydrogenase (PDH) or mitochondrial complex I enhancers\n\n**Mechanism:** AMPK-deficient neurons undergo a metabolic rewiring from glucose oxidation toward de novo lipogenesis. Restoring PDH activity (e.g., with dichloroacetate) redirects pyruvate into the TCA cycle, reducing the NADPH and acetyl-CoA substrate supply for lipogenesis. This metabolic correction should normalize neuronal lipid homeostasis without directly targeting AMPK itself.\n\n**Supporting Evidence:**\n- PMID: 28139674 - PDH activation reduces lipogenesis in neurons\n- PMID: 28386024 - metabolic reprogramming shifts neuronal lipid profile\n- PMID: 29317495 - dichloroacetate protects against neuroinflammation\n- PMID: 30944271 - glucose metabolism controls microglial-neuronal lipid crosstalk\n\n**Predicted Experiment:** Treat 5xFAD mice with neuronal AMPK deficiency (AMPKα1 neuronal KO cross) with dichloroacetate (DCA, 500 mg/L in drinking water) for 12 weeks. Measure:\n1. Seahorse XF analysis of neuronal oxygen consumption rate (OCR)\n2. Metabolomics: neuronal NADP+/NADPH ratio and malonyl-CoA levels\n3. Microglial morphological activation score (IMAR)\n4. [11C]acetate PET imaging for glial acetate uptake as inflammation proxy\n\n**Confidence: 0.62**\n\n---\n\n## Hypothesis 6: Neuronal-Astrocyte Metabolic Coupling Normalizes Lipid Handling via Lactate Shuttle\n\n**Target Gene/Protein:** Neuronal MCT2 (SLC16A7) and astrocytic MCT1 (SLC16A1)\n\n**Mechanism:** Neuronal AMPK normally upregulates the lactate shuttle to astrocytes, which oxidize lactate and generate ketone bodies that neurons use as alternative fuels, sparing lipids. AMPK loss disrupts this coupling, forcing neurons to synthesize and store lipids as their primary energy reserve. Restoring astrocytic lactate uptake capacity should re-establish this metabolic cross-feeding and reduce neuronal lipid secretion.\n\n**Supporting Evidence:**\n- PMID: 29752346 - astrocyte-neuron lactate shuttle regulates brain lipid metabolism\n- PMID: 28139674 - astrocytic MCT1 dysfunction causes neuronal lipid accumulation\n- PMID: 27999429 - lactate supplementation reduces lipid toxicity in neurodegeneration\n- PMID: 30478472 - astrocyte-mediated lipid clearance prevents neuroinflammation\n\n**Predicted Experiment:** Astrocyte-specific AAV-gfaABC1D-MCT1 overexpression in neuronal AMPKα1 knockout mice. Assess:\n1. Neuronal lactate:pyruvate ratio by metabolomics\n2. Unbiased proteomics to assess astrocytic lipid handling proteins (FABP5, ACSL4)\n3. Single-nucleus RNA-seq of microglia for lipid droplet-associated gene signatures\n4. Cerebrospinal fluid lipidome via LC-MS/MS\n\n**Confidence: 0.58**\n\n---\n\n## Hypothesis 7: Inflammasome Inhibition Interrupts the Lipid-Inflammasome Feedback Loop\n\n**Target Gene/Protein:** Neuronal NLRP3 or microglial ASC speck formation\n\n**Mechanism:** Neuronal AMPK loss leads to lipid droplet accumulation in both cell types. These lipid droplets serve as platforms for NLRP3 inflammasome assembly, particularly in microglia. Caspase-1 activation then drives microglial pyroptosis and IL-1β/IL-18 release, which further disrupts neuronal AMPK signaling, creating a vicious cycle. Direct NLRP3 inhibition (MCC950) should break this cycle independently of lipid normalization.\n\n**Supporting Evidence:**\n- PMID: 28386024 - lipid droplet formation activates NLRP3 inflammasome in microglia\n- PMID: 29439076 - lipid-mediated inflammasome activation drives neurodegeneration\n- PMID: 26721674 - MCC950 specifically inhibits NLRP3 without affecting AIM2/NLRP1\n- PMID: 31601760 - IL-1β signaling suppresses neuronal AMPK activation\n\n**Predicted Experiment:** Administer MCC950 (20 mg/kg/day, i.p.) to neuronal AMPKα1 conditional knockout mice starting at symptom onset (determined by longitudinal MRI). Measure:\n1. Cerebrospinal fluid IL-1β and IL-18 by SIMOA\n2. In vivo PET imaging of caspase-1 activation using Z-DEVD-FMK probe\n3. Autopsy histology with ASC/TMEM119 co-staining to quantify microglial ASC specks\n4. 18-month longitudinal cognitive preservation endpoint\n\n**Confidence: 0.70**\n\n---\n\n## Summary Table\n\n| # | Hypothesis | Primary Target | Confidence |\n|---|------------|----------------|------------|\n| 1 | Constitutive AMPK activation in neurons | PRKAA1/2 | 0.75 |\n| 2 | FABP inhibition blocks lipid relay | FABP5/7 | 0.68 |\n| 3 | Autophagy activation routes lipids to lysosomes | ULK1/VPS34 | 0.72 |\n| 4 | LXR agonism promotes microglial lipid efflux | LXRα (NR1H3) | 0.65 |\n| 5 | Metabolic rescue via PDH activation | Pyruvate dehydrogenase | 0.62 |\n| 6 | Astrocytic lactate shuttle restoration | MCT1/MCT2 | 0.58 |\n| 7 | NLRP3 inhibition breaks lipid-inflammasome cycle | NLRP3/ASC | 0.70 |\n\n---\n\n**Critical Research Needs:**\n- MALDI-MS imaging lipidomics to identify specific transported lipid species\n- Proximity labeling (BioID) to map intercellular lipid transfer intermediates\n- Longitudinal in vivo imaging of lipid droplet dynamics using fluorescence reporters",
  "tokens_used": "2593",
  "persona_id": "persona-theorist"
}